| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/20/2004 | US20040096953 Thrombin derivatives and process for producing the same, anhydrothrombin derivatives and process for producing the same, platelet agglutination-inducing composition, method of inducing platelet agglutination, clinical test reagents, clinical test method, thrombosis inhibitors, adsorbent and process for producing the same, |
| 05/20/2004 | US20040096925 Identifying enzyme inhibitors for treatment of skin, allergic and inflammatory disorders; cosmetics |
| 05/20/2004 | US20040096894 Three dimensional structure of cell surface glycoprotein for screening and designing drugs for treatment of inflammation |
| 05/20/2004 | US20040096888 Comprises nucleotide sequences coding cyclin dependent kinase (PELOTA) for diagnosis, treatment, prognosis and prevention of cell proliferative, cardoivascular, inflammatory, arthritic disorders |
| 05/20/2004 | US20040096886 Using sodium channel (SCNA) expresion to detect nervous system disorders; antitpileptic agents |
| 05/20/2004 | US20040096885 Using sodium channel (SCNA) expresion to detect nervous system disorders; antitpileptic agents |
| 05/20/2004 | US20040096877 For diagnosis/treatment/prevention of inflammation/asthma/ allergies |
| 05/20/2004 | US20040096848 Oligomeric compounds for the modulation HIF-1alpha expression |
| 05/20/2004 | US20040096513 Systemically minimizing the inflammatory effects of TNF- alpha are disclosed. The compositions include particles of bioactive glass with a particle size less than about 20 mu m, alone or in combination with anti-inflammatory agents and |
| 05/20/2004 | US20040096494 Composition in the form of lipoglobules which comprises (a) one or more NO-releasing NSAID(s); (b) one or more surfactants and water as well as a composition for pain and inflamation |
| 05/20/2004 | US20040096450 Determining the prophylactic suitability and quality control of compositions, such as intravenous immunoglobulin mixtures and Fac proteins for use in such methods, of preparing compositions for treating such disorders. |
| 05/20/2004 | US20040096442 Modified anti-egfr antibodies with reduced immunogenicity |
| 05/20/2004 | US20040096435 Methods for screening compounds that modulate lipid metabolism |
| 05/20/2004 | US20040096423 Use of a triple combination comprising a 5ht3 antagonist, a 5ht4agonist and a laxative for promoting intestinal lavage |
| 05/19/2004 | EP1420027A2 Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds |
| 05/19/2004 | EP1420026A2 Use of conjugates of phytosterol or phytostanol with ascorbic acid in treating or preventing cardiovascular disease, and compositions thereof |
| 05/19/2004 | EP1420020A1 4-oxoimidazolidine-2-spiropiperidine derivative |
| 05/19/2004 | EP1420017A1 1,2-dihydro-2-oxo-1,8-naphthyridine derivative |
| 05/19/2004 | EP1420016A1 Crystal and process for producing the same |
| 05/19/2004 | EP1420011A1 Compounds usefulfor treating allergic and inflammatory diseases |
| 05/19/2004 | EP1419783A2 Use of a composition comprising an exendin or a compound derived therefrom and a pharmaceutical carrier |
| 05/19/2004 | EP1419777A1 Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors |
| 05/19/2004 | EP1419773A2 4-Phenylpiperidine derivatives as modulators of dopamine neurotransmission |
| 05/19/2004 | EP1419771A1 Preventive and/or remedial agent for disease attributable to arteriosclerotic activity |
| 05/19/2004 | EP1419769A1 Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides |
| 05/19/2004 | EP1419767A1 Remedial agent for cardiac failure |
| 05/19/2004 | EP1419764A1 Use of an association of synergic calcium channel blocker agents for preventing or treating wrinkles and fine lines |
| 05/19/2004 | EP1419270A2 Method for determining chromatin structure |
| 05/19/2004 | EP1419264A2 Kinases and phosphatases |
| 05/19/2004 | EP1419256A2 Conjugates for the modulation of immune responses |
| 05/19/2004 | EP1419244A2 Electrodes coated with treating agent and uses thereof |
| 05/19/2004 | EP1419241A2 Improved nitroreductase enzymes |
| 05/19/2004 | EP1419179A2 Antigen binding domains from fish |
| 05/19/2004 | EP1419178A1 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use |
| 05/19/2004 | EP1419173A2 Peptides that bind to atherosclerotic lesions |
| 05/19/2004 | EP1419171A1 Methods for purification of an activated peg solution and for the synthesis of a modified hemoglobin solution |
| 05/19/2004 | EP1419163A1 Tricyclic imidazopyridines |
| 05/19/2004 | EP1419162A1 Substituted-aryl 7-aza 2.2.1]bicycloheptanes for the treatment of disease |
| 05/19/2004 | EP1419161A1 Substituted-heteroaryl-7-aza 2.2.1]bicycloheptanes for the treatment of disease |
| 05/19/2004 | EP1419159A1 1-alkyl 0r 1-cycloalkyltriazolo 4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
| 05/19/2004 | EP1419158A1 Pteridinone derivatives as modulators of chemokine receptor activity |
| 05/19/2004 | EP1419157A2 HETEROCYCLIC COMPOUND BASED ON N sp 6 /sp −SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE |
| 05/19/2004 | EP1419156A1 Alkyl-substituted imidazopyridines for the treatment of gastrointestinal disorders |
| 05/19/2004 | EP1419153A1 Rapamycin dialdehydes |
| 05/19/2004 | EP1419151A1 Chrystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof |
| 05/19/2004 | EP1419150A2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 05/19/2004 | EP1419143A1 24-sulfur-substituted analogs of 1alpha,25-dihydroxy vitamin d3 |
| 05/19/2004 | EP1419138A1 N- (1-dimethylaminocycloalkyl)methyl]benzamide derivatives |
| 05/19/2004 | EP1418949A2 Inhibitor of dna methylation |
| 05/19/2004 | EP1418941A2 Vaccination against the feline immunodeficiency virus |
| 05/19/2004 | EP1418937A2 Enhancing organ maturity in neonates and predicting their duration of intensive care |
| 05/19/2004 | EP1418936A2 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio. |
| 05/19/2004 | EP1418930A2 Mucosal repair by tff2 peptides |
| 05/19/2004 | EP1418921A1 Anti-tumour 2-alkoxyestradiol sulfamates |
| 05/19/2004 | EP1418920A1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| 05/19/2004 | EP1418917A1 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
| 05/19/2004 | EP1418916A1 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer |
| 05/19/2004 | EP1418912A2 Isoxazolopyridinones |
| 05/19/2004 | EP1418910A1 Methods for inhibiting or reversing tau filament formation polymerization |
| 05/19/2004 | EP1418909A2 2-amino-4, 5-trisubstituted thiaolyl derivatives and their use against autoimmune diseases |
| 05/19/2004 | EP1418908A1 Compounds for eliminating and/or relieving anhedonia |
| 05/19/2004 | EP1418907A1 Novel alpha adrenergic agents |
| 05/19/2004 | EP1418904A2 Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| 05/19/2004 | EP1418900A1 Selective estrogen receptor modulators |
| 05/19/2004 | EP1418896A2 Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| 05/19/2004 | EP1418893A1 Compositions and techniques for localized therapy of restenosis |
| 05/19/2004 | EP1418889A2 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 05/19/2004 | EP1418876A2 Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
| 05/19/2004 | EP1418814A2 Production of transduced hematopoietic progenitor cells |
| 05/19/2004 | EP1289987B1 4-(2-phenylthiazol-5-yl)-1,4-diazabicyclo- 3.2.2]nonane derivatives, preparation and therapeutic use thereof |
| 05/19/2004 | EP1263745B1 Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase |
| 05/19/2004 | EP1147084B1 Phenylsulphonyl derivatives as 5-ht receptor ligands |
| 05/19/2004 | EP1131308B1 New piperazine and piperidine compounds |
| 05/19/2004 | EP1124428A4 Stromal cell use |
| 05/19/2004 | EP1086097B1 Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
| 05/19/2004 | EP1047664B1 Novel tricyclic compounds, preparation method and pharmaceutical compositions containing same |
| 05/19/2004 | EP1034164B1 Substituted beta-alanine derivatives as cell adhesion inhibitors |
| 05/19/2004 | EP1027342B1 Cyclopentene derivatives useful as antagonists of the motilin receptor |
| 05/19/2004 | EP1025102B1 Bicyclic kinase inhibitors |
| 05/19/2004 | EP1017810B1 Agonist and antagonist peptides of carcinoembryonic antigen (cea) |
| 05/19/2004 | EP1011734B1 Gene therapy vehicle comprising dermal sheath tissue |
| 05/19/2004 | EP1009738B1 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 05/19/2004 | EP0984965B1 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors |
| 05/19/2004 | EP0942722B1 Tetrahydro-beta-carboline compounds |
| 05/19/2004 | EP0801572B1 Composition for inhibiting intimal hyperplasia using pdgf antagonists and heparin |
| 05/19/2004 | EP0637237B1 Calcium receptor-active molecules |
| 05/19/2004 | DE60003103T2 Substituierte dimere Verbindungen Verfahren zu deren Herstellung und deren pharmazeutischen Zusammensetzungen Substituted dimeric compounds process for their preparation and their pharmaceutical compositions |
| 05/19/2004 | DE10251028A1 Verwendung von Progesteron oder einem Progesteronrezeptor-Agonisten zur Hemmung der Steroidsynthese Use of progesterone or a progesterone receptor agonists for the inhibition of steroid synthesis |
| 05/19/2004 | CN1498237A Process for preparing lactic acid oligomer |
| 05/19/2004 | CN1498226A Thrombin derivatives and its process for production, anhydrothrombin derivatives and its production method, platelet agglutination-inducing compositions, method of inducing platelet agglutination,... |
| 05/19/2004 | CN1498224A Novel peptides as NS3-serine protease inhibitors of hepatitiscvirus |
| 05/19/2004 | CN1498221A Nucleoside derivatives as inhibitors of RNA-dependent PNA viral polymerase |
| 05/19/2004 | CN1498218A Imidazo-pyrimidine derivatives as ligands for GABA receptors |
| 05/19/2004 | CN1498217A Heterocyclic compounds for aging-related and diabetic vascular complications |
| 05/19/2004 | CN1498211A Aniline derivative using as phosphodiesterase 4 inhibitor |
| 05/19/2004 | CN1498210A MCH antagonists and their use in treatment of obesity |
| 05/19/2004 | CN1498209A 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6ligands |
| 05/19/2004 | CN1498205A Aryl and biaryl compounds having MCH modulatory activity |
| 05/19/2004 | CN1498115A Hydroxyalkyl starch-active agent-conjugate |
| 05/19/2004 | CN1498114A Pharmaceutical composition having reduced tendency for drug crystallization |